Multicenter, Prospectively Defined Observational Registry With Retrospective Data Collection, Evaluating Premature and Term-Near-Term Neonates With Pulmonary Hypertension Receiving Inhaled Nitric Oxide Via Invasive or Noninvasive Ventilation
Phase of Trial: Phase IV
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PaTTerN
- Sponsors Mallinckrodt Inc.
- 06 May 2019 Results of planned interim analysis presented in a Mallinckrodt Inc. media release.
- 03 Aug 2017 New trial record
- 01 Aug 2017 According to a Mallinckrodt Pharmaceuticals media release, the first patient has been enrolled in this trial.